Luciano Costa, MD PhD; ASH 2025: CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Press Pass | Lawrence on Prep for Patriots' Run Defense, Responding & Building Trust 11 min · 23 Sep 2026 · The Jacksonville Jaguars Official Podcast Network

Iran Enters the War of Words; The AI Agenda for the Trump-Xi Summit 26 min · 23 Sep 2026 · Here's the Scoop

Trump vs. the media 21 min · 23 Sep 2026 · The NPR Politics Podcast

Trump meets Xi: what's at stake? 19 min · 23 Sep 2026 · Business Daily

Musings About the Agentic Future 22 min · 23 Sep 2026 · Motley Fool Hidden Gems Investing

The Reign of Spain 54 min · 23 Sep 2026 · Football Daily

Report any issue

Source

Recorded14 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315692

Show notes

Dr. Luciano Costa discusses the findings from the CARTITUDE-4 study at the ASH 2025 Annual Meeting in Orlando. The study demonstrates that ciltacabtagene autoleucel CAR-T cell therapy provides significant long-term progression-free survival for patients with standard-risk relapsed or refractory multiple myeloma, even as early as second-line treatment. The findings suggest profound benefits in this patient population.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in